Evidence map›Paper›PMID 40473623›Full record

ArticleNature communications2025

An end-to-end attention-based approach for learning on graphs.

David Buterez, Jon Paul Janet, Dino Oglic, Pietro Liò

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Attention-Guided Multi-View Contrastive Learning for Predicting Sparse Drug-Gene Associations.Interdisciplinary sciences, computational life sciences · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

David ButerezDepartment of Computer Science and Technology, University of Cambridge, Cambridge, UK. db804@cantab.ac.uk.ORCID http://orcid.org/0000-0001-6558-0833
Jon Paul JanetMolecular AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID http://orcid.org/0000-0001-7825-4797
Dino OglicCentre for AI, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Pietro LiòDepartment of Computer Science and Technology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-0540-5053

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There has been a recent surge in transformer-based architectures for learning on graphs, mainly motivated by attention as an effective learning mechanism and the desire to supersede the hand-crafted operators characteristic of message passing schemes. However, concerns over their empirical effectiveness, scalability, and complexity of the pre-processing steps have been raised, especially in relation to much simpler graph neural networks that typically perform on par with them across a wide range of benchmarks. To address these shortcomings, we consider graphs as sets of edges and propose a purely attention-based approach consisting of an encoder and an attention pooling mechanism. The encoder vertically interleaves masked and vanilla self-attention modules to learn an effective representation of edges while allowing for tackling possible misspecifications in input graphs. Despite its simplicity, the approach outperforms fine-tuned message passing baselines and recently proposed transformer-based methods on more than 70 node and graph-level tasks, including challenging long-range benchmarks. Moreover, we demonstrate state-of-the-art performance across different tasks, ranging from molecular to vision graphs, and heterophilous node classification. The approach also outperforms graph neural networks and transformers in transfer learning settings and scales much better than alternatives with a similar performance level or expressive power.

Identifiers

PMID40473623
PMCPMC12141427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.